Literature DB >> 22075627

CXCR4/CXCL12 expression profile is associated with tumor microenvironment and clinical outcome of liver metastases of colorectal cancer.

Nozomu Sakai1, Hiroyuki Yoshidome, Takashi Shida, Fumio Kimura, Hiroaki Shimizu, Masayuki Ohtsuka, Dan Takeuchi, Masahiro Sakakibara, Masaru Miyazaki.   

Abstract

Interaction between CXCR4 and CXCL12 plays a role in tumor progression. The present study examined CXCR4, CXCL12 and CD133 expression in liver metastases of colorectal cancer (CLM) and determined whether the expression profiles affect the tumor microenvironment and thus progression, and whether they could serve as a prognostic marker for survival. Liver metastases of colorectal cancer collected from 92 patients were evaluated by CXCR4, CXCL12 and CD133 immunohistochemistry and clinicopathological data were analyzed. The expression profile of CXCR4 was determined in the colorectal cancer cell line, SW48. The expression of cytoplasmic CXCR4 was higher in 36 (39%) patients than that indicated by CXCR4 staining intensity of hepatocytes. High levels of nuclear CXCR4 expression in 23 (25%) patients significantly correlated with CXCL12 expression in hepatocytes. Nuclear CXCR4 expression was increased in the cancer cells after exposure to CXCL12. Univariate and multivariate analyses demonstrated that the high levels of nuclear CXCR4 and CXCL12 expression in hepatocytes were significantly better prognostic factors for overall and hepatic disease-free survival in patients with CLM. The expression of CXCR4 and CXCL12 in CLM may have an interactive effect that could alter the tumor microenvironment. CXCR4 expression in metastatic liver tumors together with the upregulation of CXCL12 in hepatocytes may help to predict the clinical outcomes of patients with CLM after hepatectomy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22075627     DOI: 10.1007/s10585-011-9433-5

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  46 in total

1.  Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome.

Authors:  Joseph Kim; Takuji Mori; Steven L Chen; Farin F Amersi; Steve R Martinez; Christine Kuo; Roderick R Turner; Xing Ye; Anton J Bilchik; Donald L Morton; Dave S B Hoon
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

2.  Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence.

Authors:  Edward H Lin; Manal Hassan; Yanan Li; Hua Zhao; Ajay Nooka; Elizabeth Sorenson; Keping Xie; Richard Champlin; Xifeng Wu; Donghui Li
Journal:  Cancer       Date:  2007-08-01       Impact factor: 6.860

3.  Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression.

Authors:  T Koshiba; R Hosotani; Y Miyamoto; J Ida; S Tsuji; S Nakajima; M Kawaguchi; H Kobayashi; R Doi; T Hori; N Fujii; M Imamura
Journal:  Clin Cancer Res       Date:  2000-09       Impact factor: 12.531

4.  Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival.

Authors:  Joseph Kim; Hiroya Takeuchi; Stella T Lam; Roderick R Turner; He-Jing Wang; Christine Kuo; Leland Foshag; Anton J Bilchik; Dave S B Hoon
Journal:  J Clin Oncol       Date:  2005-04-20       Impact factor: 44.544

5.  Liver resection for colorectal metastases.

Authors:  Y Fong; A M Cohen; J G Fortner; W E Enker; A D Turnbull; D G Coit; A M Marrero; M Prasad; L H Blumgart; M F Brennan
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

6.  Hepatic resection for colorectal metastases: analysis of prognostic factors.

Authors:  S Ambiru; M Miyazaki; T Isono; H Ito; K Nakagawa; H Shimizu; K Kusashio; S Furuya; N Nakajima
Journal:  Dis Colon Rectum       Date:  1999-05       Impact factor: 4.585

7.  Nuclear localization of EGF receptor and its potential new role as a transcription factor.

Authors:  S Y Lin; K Makino; W Xia; A Matin; Y Wen; K Y Kwong; L Bourguignon; M C Hung
Journal:  Nat Cell Biol       Date:  2001-09       Impact factor: 28.824

8.  Tissue microenvironment modulates CXCR4 expression and tumor metastasis in neuroblastoma.

Authors:  Libo Zhang; Herman Yeger; Bikul Das; Meredith S Irwin; Sylvain Baruchel
Journal:  Neoplasia       Date:  2007-01       Impact factor: 5.715

9.  Significance of monocyte chemoattractant protein-1 in angiogenesis and survival in colorectal liver metastases.

Authors:  Hiroyuki Yoshidome; Hirohiko Kohno; Takashi Shida; Fumio Kimura; Hiroaki Shimizu; Masayuki Ohtsuka; Yukio Nakatani; Masaru Miyazaki
Journal:  Int J Oncol       Date:  2009-04       Impact factor: 5.650

10.  Disrupted expression of CXCL5 in colorectal cancer is associated with rapid tumor formation in rats and poor prognosis in patients.

Authors:  Frank M Speetjens; Peter J K Kuppen; Maro H Sandel; Anand G Menon; Danny Burg; Cornelis J H van de Velde; Rob A E M Tollenaar; Hans J G M de Bont; J Fred Nagelkerke
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

View more
  18 in total

1.  Tumour Microenvironment: Overview with an Emphasis on the Colorectal Liver Metastasis Pathway.

Authors:  Alexandros Giakoustidis; Satvinder Mudan; Thorsten Hagemann
Journal:  Cancer Microenviron       Date:  2014-10-03

2.  CXCR4/TGF-β1 mediated self-differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and promoted colorectal carcinoma development.

Authors:  Hao-Xiang Tan; Zhi-Gang Xiao; Tao Huang; Zhi-Xue Fang; Yu Liu; Zhong-Cheng Huang
Journal:  Cancer Biol Ther       Date:  2019-12-10       Impact factor: 4.742

3.  Expression of CXCR-4 and IDO in human colorectal cancer: An immunohistochemical approach.

Authors:  Masaichi Ogawa; Michiaki Watanabe; Takuo Hasegawa; Kohei Ichihara; Kazuhiko Yoshida; Katsuhiko Yanaga
Journal:  Mol Clin Oncol       Date:  2017-04-04

4.  Differential expression of SDF-1 isoforms in bladder cancer.

Authors:  Miguel Gosalbez; Marie C Hupe; Soum D Lokeshwar; Travis J Yates; John Shields; Muthu K Veerapen; Axel S Merseburger; Charles J Rosser; Mark S Soloway; Vinata B Lokeshwar
Journal:  J Urol       Date:  2013-11-26       Impact factor: 7.450

5.  P300 Acetyltransferase Mediates Stiffness-Induced Activation of Hepatic Stellate Cells Into Tumor-Promoting Myofibroblasts.

Authors:  Changwei Dou; Zhikui Liu; Kangsheng Tu; Hongbin Zhang; Chen Chen; Usman Yaqoob; Yuanguo Wang; Jialing Wen; Jan van Deursen; Delphine Sicard; Daniel Tschumperlin; Hongzhi Zou; Wei-Chien Huang; Raul Urrutia; Vijay H Shah; Ningling Kang
Journal:  Gastroenterology       Date:  2018-02-15       Impact factor: 22.682

6.  CXCR4, CXCL12 and the relative CXCL12-CXCR4 expression as prognostic factors in colon cancer.

Authors:  Luka Stanisavljević; Jörg Aßmus; Kristian Eeg Storli; Sabine Maria Leh; Olav Dahl; Mette Pernille Myklebust
Journal:  Tumour Biol       Date:  2015-12-17

Review 7.  A meta-analysis for C-X-C chemokine receptor type 4 as a prognostic marker and potential drug target in hepatocellular carcinoma.

Authors:  Fei Hu; Lin Miao; Yu Zhao; Yuan-Yuan Xiao; Qing Xu
Journal:  Drug Des Devel Ther       Date:  2015-07-15       Impact factor: 4.162

8.  Joint network and node selection for pathway-based genomic data analysis.

Authors:  Shandian Zhe; Syed A Z Naqvi; Yifan Yang; Yuan Qi
Journal:  Bioinformatics       Date:  2013-06-08       Impact factor: 6.937

9.  The expression of chemokine receptors CXCR3 and CXCR4 in predicting postoperative tumour progression in stages I-II colon cancer: a retrospective study.

Authors:  Changzheng Du; Yunfeng Yao; Weicheng Xue; Wei-Guo Zhu; Yifan Peng; Jin Gu
Journal:  BMJ Open       Date:  2014       Impact factor: 2.692

10.  CD164 regulates the tumorigenesis of ovarian surface epithelial cells through the SDF-1α/CXCR4 axis.

Authors:  Ai-Fang Huang; Min-Wei Chen; Shih-Ming Huang; Chu-Lien Kao; Hung-Cheng Lai; James Yi-Hsin Chan
Journal:  Mol Cancer       Date:  2013-10-05       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.